Skip to main content
. 2018 Aug 30;3(6):e000305. doi: 10.1136/esmoopen-2017-000305

Table 2.

Univariate and multivariate analyses with respect to recurrence-free survival in breast cancer subtypes

Univariate analysis Multivariate analysis
HR 95% CI P values HR 95% CI P values
All breast cancer (n=129)
 Age (≤56 years) 1.406 0.729 to 2.755 0.309
 Tumour size (>2 cm) 1.098 0.434 to 3.693 0.859
 Lymph node (+) 2.004 0.895 to 5.342 0.095
 Ki-67 (>14) 1.012 0.523 to 1.974 0.971
 Subtype (TNBC) 1.494 0.553 to 4.706 0.441
 Pathological response (non-PR) 6.327 2.893 to 13.133 <0.001 5.260 2.373 to 11.145 <0.001
 TIL (%) change (low) 1.276 0.656 to 2.536 0.473
 CD8 change (low) 3.114 1.430 to 7.773 0.003 2.304 1.052 to 5.776 0.036
 FOXP3 change (high) 1.978 0.996 to 3.894 0.051
 CFR change (low) 5.612 2.581 to 14.001 <0.001 4.663 2.133 to 11.682 <0.001
TNBC (n=39)
 Age (≤56 years) 1.547 0.491 to 5.252 0.455
 Tumour size (>2 cm) 0.261 0.066 to 1.721 0.139
 Lymph node (+) 0.934 0.279 to 4.212 0.919
 Ki-67 (>14) 1.138 0.358 to 4.264 0.832
 Pathological response (non-PR) 25.642 6.873 to 123.724 <0.001 34.290 7.314 to 265.738 <0.001
 TIL (%) change (low) 1.701 0.542 to 5.758 0.361
 CD8 change (low) 2.339 0.697 to 10.551 0.177
 FOXP3 change (high) 2.106 0.660 to 7.922 0.212
 CFR change (low) 11.420 2.215 to 208.742 0.002 13.021 2.241 to 258.136 0.002
HRBC (n=77)
 Age (≤56 years) 1.182 0.475 to 2.982 0.717
 Tumour size (>2 cm) 3.622 0.743 to 65.248 0.128
 Lymph node (+) 2.803 0.796 to 17.749 0.118
 Ki-67 (>14) 0.781 0.305 to 1.969 0.597
 Pathological response (non-PR) 2.132 0.488 to 6.625 0.277
 TIL (%) change (low) 1.069 0.404 to 2.885 0.892
 CD8 change (low) 3.167 1.134 to 11.196 0.027 2.746 0.976 to 9.741 0.056
 FOXP3 change (high) 1.985 0.682 to 5.237 0.196
 CFR change (low) 4.740 1.779 to 14.833 0.002 4.377 1.641 to 13.712 0.003

Values in parentheses are 95% CIs.

CFR, CD8/FOXP3 ratio; FOXP3, forkhead box protein; HRBC, hormone receptor-positive breast cancer; PR, partial response; TIL, tumour-infiltrating lymphocyte; TNBC, triple-negative breast cancer.